



## **XBiotech Announces Grand Opening Date for New Commercial Manufacturing Facility**

August 22, 2016

AUSTIN, Texas, Aug. 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIO), developer of next-generation True Human™ therapeutic antibodies, today announced the timing for the grand opening of its state-of-the-art commercial manufacturing facility. The grand opening ceremony will take place on September 15, 2016 at 10 a.m. local time at the building's location in Austin, Texas. It will include a ribbon-cutting ceremony, tour of the facility and a brief talk by XBiotech's management.

The nearly 40,000 square foot facility is on XBiotech's own 48-acre location just 15 minutes from the Texas capital in Austin. The building will provide a significant increase in the company's manufacturing and quality operations in anticipation of commercialization of the Company's product pipeline. The new facility will increase about ten-fold the Company's current production capacity. Completion of this building is the first phase in the Company's plan to develop the 48-acre property to house additional production facilities, laboratories and administrative operations, creating a headquarter campus as the center of its global operations.

For more information on the opening or if you would like to attend please contact:

Ashley Otero

[aotero@xbiotech.com](mailto:aotero@xbiotech.com)

512-386-2930

### **About XBiotech's Manufacturing Technology**

XBiotech's manufacturing process uses innovative technologies to reduce infrastructure and go-forward operating costs typically needed for production of biological drugs. At the heart of XBiotech's process is a single-use bioreactor that is discarded after growth of the drug-producing cells. While XBiotech's novel manufacturing platform reduces infrastructure costs and operating complexity, it also minimizes lead times, simplifies the ability to comply with manufacturing regulations and improves production flexibility compared to systems currently used in the industry. Operations at the new facility will take XBiotech's core technology to a new level, with a purpose-built infrastructure that incorporates numerous innovations to increase manufacturing throughput and simplicity.

### **About True Human™ Therapeutic Antibodies**

Unlike previous generations of antibody therapies, XBiotech's True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

### **About XBiotech**

XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit [www.xbiotech.com](http://www.xbiotech.com).

### **Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplates," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact

Ashley Otero

[aotero@xbiotech.com](mailto:aotero@xbiotech.com)

512-386-2930



XBiotech, Inc